ELDN (Eledon Pharmaceuticals) Current Accrued Expense: $5.42 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELDN Eledon Pharmaceuticals Inc ELDN
26 GF Score
Price $3.20
! 1 Warning Sign
View Full Analysis

What is Eledon Pharmaceuticals Current Accrued Expense?

Eledon Pharmaceuticals ELDN -3.61% 26 Current Accrued Expense is $5.42 Mil as of Jun. 2026. GuruFocus rates ELDN with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Eledon Pharmaceuticals's Current Accrued Expense for the quarter that ended in Jun. 2026 was $5.42 Mil.

Eledon Pharmaceuticals's quarterly Current Accrued Expense declined from Dec. 2025 ($10.18 Mil) to Mar. 2026 ($4.86 Mil) but then increased from Mar. 2026 ($4.86 Mil) to Jun. 2026 ($5.42 Mil).

Eledon Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2023 ($0.54 Mil) to Dec. 2024 ($3.83 Mil) and increased from Dec. 2024 ($3.83 Mil) to Dec. 2025 ($10.18 Mil).

Eledon Pharmaceuticals Current Accrued Expense Related Terms

Eledon Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Eledon Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eledon Pharmaceuticals Current Accrued Expense Chart

Eledon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 2.00 0.54 3.83 10.18

Eledon Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.30 6.11 10.18 4.86 5.42
ELDN
26GF Score
Eledon Pharmaceuticals Inc ELDN
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eledon Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $5.42 Mil mean?
Eledon Pharmaceuticals (ELDN) has a Current Accrued Expense of $5.42 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Eledon Pharmaceuticals and its competitors.
Is Eledon Pharmaceuticals' Current Accrued Expense too high?
Eledon Pharmaceuticals' current Current Accrued Expense is $5.42 Mil. Overall, Eledon Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Eledon Pharmaceuticals' Current Accrued Expense compare to NMRA and ALXO?
Eledon Pharmaceuticals' Current Accrued Expense of $5.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Eledon Pharmaceuticals and its competitors. Eledon Pharmaceuticals's current Current Accrued Expense is $5.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eledon Pharmaceuticals stock overvalued right now?
Eledon Pharmaceuticals (ELDN) has a current Current Accrued Expense of $5.42 Mil. The current Current Accrued Expense is $5.42 Mil. Eledon Pharmaceuticals' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Eledon Pharmaceuticals (ELDN), the current Current Accrued Expense is $5.42 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eledon Pharmaceuticals Business Description

Other Exchanges 2TK:Germany
Address 19800 MacArthur Boulevard, Suite 250, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
26GF Score

Get the complete analysis for ELDN

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.20
Price